Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hospira, Inc.
WARNING LETTER
•Hospira, Inc.•February 23, 2010

Hospira, Inc. – FDA Warning Letter, Feb 23, 2010

Record Details

This FDA Warning Letter (10-ATL-12) was issued to Hospira, Inc. following inspections of their pharmaceutical and device manufacturing facilities in Rocky Mount and Clayton, North Carolina, from January 12 - February 23, 2010. The inspections revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211) and Quality System (QS) regulations for medical devices (21 CFR Part 820), rendering their drug products and devices adulterated.

At the Clayton facility, violations included inadequate written procedures for production and process controls, specifically failing to prevent objectionable particulate contamination (primarily stainless steel) in Liposyn, Propofol, and Cleviprex emulsion products. This was a persistent issue, leading to multiple recalls and delayed detection of contamination in expired lots. The Quality Control Unit (QCU) failed to adequately design, control, and monitor manufacturing processes, implement effective corrective actions, and timely complete investigations and Field Alert Reports. Investigations into batch failures were inadequate, failing to identify root causes or extend to other affected lots. The firm also lacked acceptance criteria for retain sample inspections and scientifically sound sampling plans for sub-visible particulates. These were repeat observations from an April 2009 inspection.

At the Rocky Mount facility, the firm lacked adequate written procedures for production and process controls, specifically failing to adequately validate mixing processes for multiple products

Company
Hospira, Inc.
Inspection date
February 23, 2010
Product type
Drugs
Office
Atlanta District Office
People
  • John R. Gridley
  • Philip S. Campbell
View Company Profile

ID · 75b973fd-bfa7-4299-89f0-4df1b3c40e19

Violation Codes10
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.100(a)21 CFR 211.22(d)21 CFR 211.19221 CFR 211.165(d)21 CFR 211.160(b)21 CFR 820.75(a)21 U.S.C. 321(h)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.